NEW YORK (GenomeWeb News) — Transgenomic said after the close of the market on Wednesday that its first quarter revenues declined 15 percent year over year.

For the three months ended March 31, the Omaha, Neb.-based molecular diagnostics firm logged total revenues of $6.3 million compared to $7.4 million in the prior-year period. Transgenomic attributed this decline primarily to lower sales in its Laboratory Services segment, reflecting higher-than-usual sales in Q1 2013 that had resulted from working down a backlog of Nuclear Mitome tests from 2012.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: self-assembly of DNA components in solution, and more.

Genetics and Molecular Research retracts two gastric cancer papers for being "substantially equal" to other papers, according to Retraction Watch.

A new analysis indicates that the Ebola virus behind the current West African outbreak is mutating at about the same rate as other Ebola viruses.

With the launch of Scott Kelly into space today, the study of him and his earthbound brother to disentangle the effects of life in space from the effects of genetics kicks off.